These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7684157)

  • 21. alpha1-Adrenergic blockers in young men with primary bladder neck obstruction.
    Yang SS; Wang CC; Hsieh CH; Chen YT
    J Urol; 2002 Aug; 168(2):571-4. PubMed ID: 12131312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
    Kirby RS
    Urology; 1995 Aug; 46(2):182-6. PubMed ID: 7542819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
    Kirby RS
    Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction.
    Kirby RS; O'Leary MP; Carson C
    BJU Int; 2005 Jan; 95(1):103-9; discussion 109. PubMed ID: 15638905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
    Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
    Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
    Fawzy A; Vashi V; Chung M; Dias N; Gaffney M
    Urology; 1999 Feb; 53(2):329-35. PubMed ID: 9933049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
    Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB
    BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months.
    Gerber GS; Contreras BA; Zagaja GP; Kim JH; Steinberg GD; Rukstalis DB
    Urology; 1997 Aug; 50(2):229-33. PubMed ID: 9255293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
    Salinas Casado J; Esteban Fuertes M; Virseda Chamorro M; Ramírez Fernández JC; Salomón Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):840-5. PubMed ID: 9463281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study.
    Fawzy A; Braun K; Lewis GP; Gaffney M; Ice K; Dias N
    J Urol; 1995 Jul; 154(1):105-9. PubMed ID: 7539853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia.
    Türkeri LN; Ozyürek M; Ersev D; Akdaş A
    Arch Esp Urol; 2001 Mar; 54(2):191-6. PubMed ID: 11341128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Single-blind study of the effect of doxazosin mesylate in benign prostatic hypertrophy].
    Siracusano S; Paoni A; Tomasi PA; Deriu M; Trombetta C; Belgrano E
    Prog Urol; 1994 Dec; 4(6):1017-21. PubMed ID: 7533030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
    Popa G; Hägele-Kaddour H; Walther C
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():103-8. PubMed ID: 16261945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
    Janknegt RA; Chapple CR
    Eur Urol; 1993; 24(3):319-26. PubMed ID: 7505224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
    Aganović D; Aganović K; Prcić A
    Med Arh; 2004; 58(3):153-6. PubMed ID: 15484855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
    Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
    Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.